| 7/21/03 |
Pro-Pharmaceuticals Appoints Noted Carbohydrate Chemist Zbigniew J. Witczak, Ph.D. to Its Scientific Advisory Board
|
| 7/15/03 |
Pro-Pharmaceuticals To Host Corporate Presentations in Denver, Austin & Chicago
|
| 7/2/03 |
Pro-Pharmaceuticals Announces Publication of Study in Peer-Reviewed Journal Carbohydrate Research
|
| 6/24/03 |
Cancer Patients Injected With Pro-Pharmaceuticals? DAVANAT?
in Phase I Clinical Trial at the Norris Cotton Cancer Center
at Dartmouth-Hitchcock Medical
|
| 6/20/03 |
Pro-Pharmaceuticals To Host Corporate Presentations
|
| 5/29/03 |
Pro-Pharmaceuticals Names Squeglia VP Investor Relations
|
| 5/14/03 |
Cancer Patients Injected With Pro-Pharmaceuticals? DAVANAT in Phase I Clinical Trial at the Ochsner Cancer Institute
|
| 4/28/03 |
Pro-Pharmaceuticals Receives Patent Allowance for Its Carbohydrate Linker Technology for Anti-Cancer Agents
|
| 4/14/03 |
Pro-Pharmaceuticals Appoints Steven Prelack to Board of Directors
|
| 4/3/03 |
Pro-Pharmaceuticals Reports Year End Results
|
| 3/20/03 |
Pro-Pharmaceuticals Appoints David Christopher as CFO
|
| 2/14/03 |
Cancer Patients Injected With Pro-Pharmaceuticals' DAVANAT in Phase I Clinical Trial At Howell, New Jersey Oncology Clinics
|
| 2/6/03 |
Pro-Pharmaceuticals Initiates Multi-Center Clinical Trials Of DAVANAT"-1 For All Solid Tumors
|
| 1/15/03 |
Pro-Pharmaceuticals Completes Private Placement
|
| 1/6/03 |
Pro-Pharmaceuticals Expands Clinical Cancer Trial to Include Additional Solid Tumors
|
| 12/30/02 |
Pro-Pharmaceuticals Engages Medidata for Real-Time Electronic Data Collection in its Clinical Cancer Trial
|
| 12/19/02 |
Pro-Pharmaceuticals Retains PRA International for Clinical Trial In Cancer Patients
|
| 12/10/02 |
Pro-Pharmaceuticals Presents Overview of Carbohydrate Technology To Enhance Existing Cancer Drugs
|
| 11/15/02 |
Pro-Pharmaceuticals Reports Third Quarter Results
|
| 10/22/02 |
Pro-Pharmaceuticals Names Medical Director for Upcoming Clinical Study.
Marilyn Pike engaged as clinical development consultant to oversee firm's Phase I drug trial
|
| 10/7/02 |
Pro-Pharmaceuticals Appoints Mildred Christian to Board of Directors.
Expert on experimental design and government compliance to serve multiple roles with firm
|
| 9/25/02 |
Pro-Pharmaceuticals Featured in Genetic Engineering News Overview of
Innovative Cancer Therapy Research
|
| 9/12/02 |
Pro-Pharmaceuticals Names University of Michigan Medical School Professor to Scientific Advisory Board. Expert on specialized protein-carbohydrate chemistry to consult on upcoming clinical trials.
|
| 9/5/02 |
Pro-Pharmaceuticals Commences Trading on NASD OTC Bulletin Board. Trading Follows FDA Approval of Human Trials With Cancer Drug Enhancement Formulation. |
| 8/26/02 |
Pro-Pharmaceuticals Reports Second Quarter Results |
| 7/29/02 |
Pro-Pharmaceuticals Receives FDA Approval for Phase I Clinical Trial
|
| 7/11/02 |
Pro-Pharmaceuticals Announces Public Reporting of Financial Results
|
